Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

NCT ID: NCT01200589

Last Updated: 2018-05-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 438 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-11
• Study Completion Date: 2016-12-19

Brief Summary

This was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6 months after completing treatment with single agent rituximab or a rituximab-containing regimen. Subjects must have attained a Complete Response or Partial Response to their last prior rituximab containing therapy lasting at least six months beyond the end of rituximab therapy. Subjects were to receive four weekly doses of single agent ofatumumab (1000 mg) or rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2 months for four additional doses. Therefore, subjects were to receive a total of eight doses of anti-CD20 antibody over 9 months. Subjects were evaluated for response after completion of the first four doses of therapy, after six doses of therapy, and after completion of study therapy. Subjects were to be followed until the end of the designated follow-up period (total study duration of 200 weeks) or until they meet the withdrawal criteria.

The primary objective of the study OMB157D 2303 was to demonstrate the efficacy of Arzerra based on the primary endpoint (Progression-free survival (PFS) as assessed by the IRC) in patients with Indolent B-cell Non-Hodgkin's Lymphoma Relapsed After Rituximab-Containing Regimen.

The Independent Data Monitoring Committee (IDMC) met on November 22, 2015 and recommended the termination of the study due to futility (cut-off date = 12Jun2015). The IDMC reviewed analyses results for progression free survival (PFS), overall response rate (ORR), and overall survival (OS). Novartis accepted this recommendation and the study was closed.

Final analysis was performed (cut-off date =19 Dec 2016). As the study was stopped for futility, the primary objective was not met and some secondary endpoints, supportive of primary objective (Duration of Response (DOR), time to next therapy, and pharmacokinetics) were removed as secondary end points.

Conditions

Non-Hodgkin's Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Ofatumumab

Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.

Group Type: EXPERIMENTAL

Ofatumumab

Intervention Type: BIOLOGICAL

liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.

Ofatumumab

Intervention Type: BIOLOGICAL

Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.

Arm B: Rituximab

Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.

Group Type: ACTIVE_COMPARATOR

Rituximab

Intervention Type: BIOLOGICAL

sourced locally from commercial stock

Rituximab

Intervention Type: BIOLOGICAL

Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.

Interventions

Ofatumumab

liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.

Intervention Type: BIOLOGICAL

Rituximab

sourced locally from commercial stock

Intervention Type: BIOLOGICAL

Ofatumumab

Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.

Intervention Type: BIOLOGICAL

Rituximab

Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.

Intervention Type: BIOLOGICAL

Other Intervention Names

Arzerra; Mabthera; Rituxan; Arzerra; Mabthera; Rituxan

Eligibility Criteria

Inclusion Criteria

1. Indolent NHL subtypes defined according to World Health Organization guidelines:

1. Follicular lymphoma Grades 1, 2, 3 A

2. Small lymphocytic lymphoma (SLL)

3. Marginal zone lymphoma

4. Lymphoplasmacytic lymphoma

2. Rituximab-sensitive iNHL, defined as a partial or complete response to their last prior treatment with rituximab or a rituximab-containing regimen lasting at least 6 months following completion of rituximab treatment.

3. Relapse or disease progression following response to prior rituximab-based therapy, as defined by 2007 RRCML criteria, which requires therapy.

4. Radiographically measurable disease, defined as: 2 or more clearly demarcated lesions/nodes with a long axis >1.5 cm and short axis ≥1.0cm. OR 1 clearly demarcated lesion/node with a long axis >2.0 cm and short axis ≥1.0cm.

5. ECOG Performance Status of 0, 1, or 2.

6. Age ≥18 years.

7. Life expectancy of at least 6 months in the opinion of the investigator.

8. The patient or their legally acceptable representative must be capable of giving written informed consent prior to performing any study-specific tests or procedures.

9. All prior treatment related non-hematologic toxicities (with the exception of alopecia) must have resolved to CTCAE (Version 4.0) ≤ Grade 2 at the time of randomization.

10. One or more of the following indications for treatment:

1. Cytopenias

2. One or more of the following lymphoma-related symptoms:

• Night sweats without signs of infection
• Unintentional weight loss (10% within the previous 6 months)
• Recurrent, unexplained fever of greater than 100.5F (38C) without signs of infection
• Fatigue which interferes with the patient's quality of life

3. Progressive or massive lymphadenopathy OR

4. Progressive or massive organomegaly French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria

1. Previous treatment with ofatumumab.

2. Previous anti-CD20 radioimmunotherapy (RIT) or non-rituximab anti-CD20 therapy (such as obinutuzumab) within 6 months prior to randomization. Patients who have received previous anti-CD20 RIT or non-rituximab anti-CD20 therapy (such as obinutuzumab) must have attained a partial or complete response lasting at least 6 months, and must have recovered from any hematologic or other toxicity.

3. Previous autologous stem cell transplantation within 6 months prior to randomization.

4. Previous allogeneic stem cell transplantation.

5. Previous anti-lymphoma monoclonal antibody therapy (excluding anti-CD20 therapy and anti-CD20 RIT), chemotherapy, glucocorticoid, or other systemic therapy for lymphoma within 3 months prior to randomization.

6. Current or previous participation in the treatment phase of another interventional clinical study within 4 weeks prior to randomization. Patients may continue in the follow-up phase of another interventional clinical study, but may not have undergone any treatment on the other study within 4 weeks prior to randomization.

7. Current or previous other malignancy within 2 years prior to randomization. Subjects who have been free of malignancy for at least 2 years, or have a history of completely resected non-melanoma skin cancer or successfully treated carcinoma in situ, are eligible.

8. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All HIV-positive patients are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy. Prophylactic antiviral and/or antibacterial antibiotics to prevent recurrence of previous infections are permitted.

9. Clinically significant cardiac disease as judged by the investigator including unstable angina, acute myocardial infarction within 6 months prior to randomization, uncontrolled congestive heart failure, and uncontrolled arrhythmia. Subjects with congestive heart disease or arrhythmias such as atrial fibrillation whose cardiac disease is well controlled on a stable medical regimen are eligible.

10. Other significant concurrent, uncontrolled medical conditions including, but not limited to, renal, hepatic, autoimmune, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which, in the investigator's opinion, will impact study participation.

11. Screening laboratory values:

1. Neutrophils < 1.5 x 10^9/L (unless due to iNHL involvement of the bone marrow)

2. Platelets < 50 x 10^9/L (unless due to iNHL involvement of the bone marrow)

3. ALT or AST > 3 x ULN

4. Alkaline phosphatase > 1.5 x ULN (unless due to lymphoma or a non-malignant, non-hepatic cause such as Paget's disease)

5. Total bilirubin > 1.5 x ULN (unless due to lymphoma or isolated, predominantly indirect hyperbilirubinemia due to Gilbert's syndrome)

12. Known or suspected inability to fully comply with study protocol

13. Because the effects of ofatumumab on fetuses and nursing infants are not known, the following are ineligible for study entry:

1. Lactating women.

2. Women with a positive pregnancy test at study entry.

3. Men with partners of childbearing potential and women of childbearing potential who are not willing to use adequate contraception from study entry through one year following last treatment dose. (Adequate contraception is defined as abstinence, oral hormonal birth control, hormonal birth control injections, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is the sole partner for a female subject. The double barrier method can be used in regions where considered acceptable and adequate, defined as condom or occlusive cap plus spermicidal agent).

14. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones).

15. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Anchorage, Alaska, United States

Novartis Investigative Site

Gilbert, Arizona, United States

Novartis Investigative Site

Hot Springs, Arkansas, United States

Novartis Investigative Site

Greenbrae, California, United States

Novartis Investigative Site

Monterey, California, United States

Novartis Investigative Site

Pleasant Hill, California, United States

Novartis Investigative Site

Rancho Mirage, California, United States

Novartis Investigative Site

Salinas, California, United States

Novartis Investigative Site

San Diego, California, United States

Novartis Investigative Site

San Pablo, California, United States

Novartis Investigative Site

Santa Monica, California, United States

Novartis Investigative Site

New Milford, Connecticut, United States

Novartis Investigative Site

Torrington, Connecticut, United States

Novartis Investigative Site

Lakeland, Florida, United States

Novartis Investigative Site

Orlando, Florida, United States

Novartis Investigative Site

Pembroke Pines, Florida, United States

Novartis Investigative Site

Port Saint Lucie, Florida, United States

Novartis Investigative Site

West Palm Beach, Florida, United States

Novartis Investigative Site

Macon, Georgia, United States

Novartis Investigative Site

Marietta, Georgia, United States

Novartis Investigative Site

Evanston, Illinois, United States

Novartis Investigative Site

Peoria, Illinois, United States

Novartis Investigative Site

Quincy, Illinois, United States

Novartis Investigative Site

Skokie, Illinois, United States

Novartis Investigative Site

Anderson, Indiana, United States

Novartis Investigative Site

Indianapolis, Indiana, United States

Novartis Investigative Site

Ames, Iowa, United States

Novartis Investigative Site

Mount Sterling, Kentucky, United States

Novartis Investigative Site

Metairie, Louisiana, United States

Novartis Investigative Site

Shreveport, Louisiana, United States

Novartis Investigative Site

Waterville, Maine, United States

Novartis Investigative Site

Silver Spring, Maryland, United States

Novartis Investigative Site

Grand Rapids, Michigan, United States

Novartis Investigative Site

Kalamazoo, Michigan, United States

Novartis Investigative Site

Jackson, Mississippi, United States

Novartis Investigative Site

Columbia, Missouri, United States

Novartis Investigative Site

Kansas City, Missouri, United States

Novartis Investigative Site

Saint Joseph, Missouri, United States

Novartis Investigative Site

Springfield, Missouri, United States

Novartis Investigative Site

Bozeman, Montana, United States

Novartis Investigative Site

Lincoln, Nebraska, United States

Novartis Investigative Site

Lincoln, Nebraska, United States

Novartis Investigative Site

Albuquerque, New Mexico, United States

Novartis Investigative Site

Albuquerque, New Mexico, United States

Novartis Investigative Site

Lake Success, New York, United States

Novartis Investigative Site

Mount Kisco, New York, United States

Novartis Investigative Site

Greensboro, North Carolina, United States

Novartis Investigative Site

Bismarck, North Dakota, United States

Novartis Investigative Site

Canton, Ohio, United States

Novartis Investigative Site

Canton, Ohio, United States

Novartis Investigative Site

Portland, Oregon, United States

Novartis Investigative Site

Danville, Pennsylvania, United States

Novartis Investigative Site

Ephrata, Pennsylvania, United States

Novartis Investigative Site

Lancaster, Pennsylvania, United States

Novartis Investigative Site

Willow Grove, Pennsylvania, United States

Novartis Investigative Site

Chattanooga, Tennessee, United States

Novartis Investigative Site

Germantown, Tennessee, United States

Novartis Investigative Site

Knoxville, Tennessee, United States

Novartis Investigative Site

Fort Sam Houston, Texas, United States

Novartis Investigative Site

Houston, Texas, United States

Novartis Investigative Site

Ogden, Utah, United States

Novartis Investigative Site

Salt Lake City, Utah, United States

Novartis Investigative Site

Fredericksburg, Virginia, United States

Novartis Investigative Site

Kennewick, Washington, United States

Novartis Investigative Site

Kirkland, Washington, United States

Novartis Investigative Site

Mount Vernon, Washington, United States

Novartis Investigative Site

Seattle, Washington, United States

Novartis Investigative Site

Seattle, Washington, United States

Novartis Investigative Site

Sequim, Washington, United States

Novartis Investigative Site

Spokane, Washington, United States

Novartis Investigative Site

Antwerp, , Belgium

Novartis Investigative Site

Antwerp, , Belgium

Novartis Investigative Site

Bruges, , Belgium

Novartis Investigative Site

Brussels, , Belgium

Novartis Investigative Site

Brussels, , Belgium

Novartis Investigative Site

Kortrijk, , Belgium

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Wilrijk, , Belgium

Novartis Investigative Site

Salvador, Estado de Bahia, Brazil

Novartis Investigative Site

Betim, Minas Gerais, Brazil

Novartis Investigative Site

Curitiba, Paraná, Brazil

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Novartis Investigative Site

Barretos, São Paulo, Brazil

Novartis Investigative Site

Jaú, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

Rio de Janeiro, , Brazil

Novartis Investigative Site

Rio de Janeiro, , Brazil

Novartis Investigative Site

Pleven, , Bulgaria

Novartis Investigative Site

Plovdiv, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Varna, , Bulgaria

Novartis Investigative Site

Moncton, New Brunswick, Canada

Novartis Investigative Site

Kitchener, Ontario, Canada

Novartis Investigative Site

Québec, Quebec, Canada

Novartis Investigative Site

Sherbrooke, Quebec, Canada

Novartis Investigative Site

Guangzhou, Guangdong, China

Novartis Investigative Site

Guangzhou, Guangdong, China

Novartis Investigative Site

Hangzhou, Zhejiang, China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Tianjin, , China

Novartis Investigative Site

Brno, , Czechia

Novartis Investigative Site

Hradec Králové, , Czechia

Novartis Investigative Site

Ostrava, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Boulogne-sur-Mer, , France

Novartis Investigative Site

Clermont-Ferrand, , France

Novartis Investigative Site

La Roche-sur-Yon, , France

Novartis Investigative Site

Le Mans, , France

Novartis Investigative Site

Montpellier, , France

Novartis Investigative Site

Pessac, , France

Novartis Investigative Site

Budapest, , Hungary

Novartis Investigative Site

Debrecen, , Hungary

Novartis Investigative Site

Győr, , Hungary

Novartis Investigative Site

Szeged, , Hungary

Novartis Investigative Site

Aichi, , Japan

Novartis Investigative Site

Kyoto, , Japan

Novartis Investigative Site

Miyagi, , Japan

Novartis Investigative Site

Nagasaki, , Japan

Novartis Investigative Site

Saitama, , Japan

Novartis Investigative Site

Tochigi, , Japan

Novartis Investigative Site

Tokyo, , Japan

Novartis Investigative Site

Tokyo, , Japan

Novartis Investigative Site

Miraflores, Lima region, Peru

Novartis Investigative Site

San Isidro, Lima region, Peru

Novartis Investigative Site

Lima, , Peru

Novartis Investigative Site

Lima, , Peru

Novartis Investigative Site

Lima, , Peru

Novartis Investigative Site

San Juan, , Puerto Rico

Novartis Investigative Site

Bratislava, , Slovakia

Novartis Investigative Site

Košice, , Slovakia

Novartis Investigative Site

Martin, , Slovakia

Novartis Investigative Site

Parktown, Gauteng, South Africa

Novartis Investigative Site

Athlone Park, Amanzimtoti, , South Africa

Novartis Investigative Site

Port Elizabeth, , South Africa

Novartis Investigative Site

Saxonwold, Johannesburg, , South Africa

Novartis Investigative Site

Busan, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Seoul, , South Korea

Novartis Investigative Site

Donetsk, , Ukraine

Novartis Investigative Site

Kyiv, , Ukraine

Novartis Investigative Site

Kyiv, , Ukraine

Novartis Investigative Site

Lviv, , Ukraine

Novartis Investigative Site

Makiivka, , Ukraine

Novartis Investigative Site

Simferopil, , Ukraine

Countries

United States; Belgium; Brazil; Bulgaria; Canada; China; Czechia; France; Hungary; Japan; Peru; Puerto Rico; Slovakia; South Africa; South Korea; Ukraine

References

Maloney DG, Ogura M, Fukuhara N, Davis J, Lasher J, Izquierdo M, Banerjee H, Tobinai K. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv. 2020 Aug 25;4(16):3886-3893. doi: 10.1182/bloodadvances.2020001942.

Reference Type: DERIVED

PMID: 32810220 (View on PubMed)

Other Identifiers

113676

Identifier Type: -

Identifier Source: org_study_id